Evaluation of Efficacy and Safety of Rituximab in Patients With Progressive Interstitial Lung Disease (ILD) With Inflammatory Component: a Multicentre Double-blind Placebo-controlled Randomized Trial

NCT05596786 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Lung Diseases

Interventions

DRUG: Rituximab
OTHER: Placebo

Sponsor

University Hospital, Tours